Search Results - "Hauschild, A"

Orbit and clock analysis of Compass GEO and IGSO satellites by Steigenberger, P., Hugentobler, U., Hauschild, A., Montenbruck, O.

“…China is currently focussing on the establishment of its own global navigation satellite system called Compass or BeiDou. At present, the Compass constellation…”
Get full text

Epidemiology of invasive cutaneous melanoma by MacKie, R. M., Hauschild, A., Eggermont, A. M. M.

“…Data are presented on the current incidence of melanoma with recent and predicted future trends illustrating a likely continuing increase in incidence. Risk…”
Get full text

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Dummer, R, Hauschild, A, Guggenheim, M, Keilholz, U, Pentheroudakis, G

Get full text

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial by Basset-Séguin, N., Hauschild, A., Kunstfeld, R., Grob, J., Dréno, B., Mortier, L., Ascierto, P.A., Licitra, L., Dutriaux, C., Thomas, L., Meyer, N., Guillot, B., Dummer, R., Arenberger, P., Fife, K., Raimundo, A., Dika, E., Dimier, N., Fittipaldo, A., Xynos, I., Hansson, J.

“…The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog pathway…”
Get full text

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study by Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

“…Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and…”
Get full text

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety by Malvehy, J., Hauschild, A., Curiel-Lewandrowski, C., Mohr, P., Hofmann-Wellenhof, R., Motley, R., Berking, C., Grossman, D., Paoli, J., Loquai, C., Olah, J., Reinhold, U., Wenger, H., Dirschka, T., Davis, S., Henderson, C., Rabinovitz, H., Welzel, J., Schadendorf, D., Birgersson, U.

“…Summary Background Even though progress has been made, the detection of melanoma still poses a challenge. In light of this situation, the Nevisense electrical…”
Get full text

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion by Dummer, R., Ascierto, P.A., Basset‐Seguin, N., Dréno, B., Garbe, C., Gutzmer, R., Hauschild, A., Krattinger, R., Lear, J.T., Malvehy, J., Schadendorf, D., Grob, J.J.

“…Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of advanced basal cell carcinoma (BCC). Until recently, vismodegib…”
Get full text

Melanoma risk in congenital melanocytic naevi: a systematic review by Krengel, S., Hauschild, A., Schäfer, T.

“…Summary Background  The risk of malignant melanoma in congenital melanocytic naevi (CMN) is a matter of controversial and ongoing debate. Objectives  The…”
Get full text

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study by McArthur, G.A., Maio, M., Arance, A., Nathan, P., Blank, C., Avril, M.-F., Garbe, C., Hauschild, A., Schadendorf, D., Hamid, O., Fluck, M., Thebeau, M., Schachter, J., Kefford, R., Chamberlain, M., Makrutzki, M., Robson, S., Gonzalez, R., Margolin, K.

“…Vemurafenib has shown activity in patients withBRAFV600 mutated melanoma with brain metastases (BM). This phase 2 study evaluated vemurafenib in patients…”
Get full text

Photodynamic therapy for actinic keratoses: procedure matters? by Hauschild, A.

Get full text

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial by Guo, J., Carvajal, R.D., Dummer, R., Hauschild, A., Daud, A., Bastian, B.C., Markovic, S.N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T.M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F.S.

“…The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with…”
Get full text

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., Keilholz, U.

Get full text

Current breathomics--a review on data pre-processing techniques and machine learning in metabolomics breath analysis by Smolinska, A, Hauschild, A-Ch, Fijten, R R R, Dallinga, J W, Baumbach, J, van Schooten, F J

“…We define breathomics as the metabolomics study of exhaled air. It is a strongly emerging metabolomics research field that mainly focuses on health-related…”
Get more information

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study by Dréno, B., Ribas, A., Larkin, J., Ascierto, P.A., Hauschild, A., Thomas, L., Grob, J.-J., Koralek, D.O., Rooney, I., Hsu, J.J., McKenna, E.F., McArthur, G.A.

“…In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free…”
Get full text

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Dummer, R., Hauschild, A., Guggenheim, M., Jost, L., Pentheroudakis, G.

Get full text

Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas by Egberts, F., Bergner, I., Krüger, S., Haag, J., Behrens, H.M., Hauschild, A., Röcken, C.

“…Although 90% of all melanomas are of cutaneous origin, some patients present with melanoma metastases of unknown origin (MUP). Commonly, in these patients an…”
Get full text

Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients by Heppt, M.V., Schlaak, M., Eigentler, T.K., Kähler, K.C., Kiecker, F., Loquai, C., Meier, F., Tomsitz, D., Brenner, N., Niesert, A.C., Thonke, R., Hauschild, A., Berking, C.

Get full text

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion by Potthoff, K., Hofheinz, R., Hassel, J.C., Volkenandt, M., Lordick, F., Hartmann, J.T., Karthaus, M., Riess, H., Lipp, H.P., Hauschild, A., Trarbach, T., Wollenberg, A.

“…Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal growth factor receptor…”
Get full text

Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors by Lewis, K D, Peris, K, Sekulic, A, Stratigos, A J, Dunn, L, Eroglu, Z, Chang, A L S, Migden, M R, Yoo, S-Y, Mohan, K, Coates, E, Okoye, E, Bowler, T, Baurain, J-F, Bechter, O, Hauschild, A, Butler, M O, Hernandez-Aya, L, Licitra, L, Neves, R I, Ruiz, E S, Seebach, F, Lowy, I, Goncalves, P, Fury, M G

“…Metastatic basal cell carcinoma (mBCC) is a rare condition with no effective second-line treatment options. Cemiplimab is an immune checkpoint inhibitor that…”
Get more information

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy by Morton, C.A., Dominicus, R., Radny, P., Dirschka, T., Hauschild, A., Reinhold, U., Aschoff, R., Ulrich, M., Keohane, S., Ekanayake‐Bohlig, S., Ibbotson, S., Ostendorf, R., Berking, C., Gröne, D., Schulze, H.J., Ockenfels, H.M., Jasnoch, V., Kurzen, H., Sebastian, M., Stege, H., Staubach, P., Gupta, G., Hübinger, F., Ziabreva, I., Schmitz, B., Gertzmann, A., Lübbert, H., Szeimies, R.‐M.

“…Summary Background Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair‐skinned individuals…”
Get full text